Events

Transforming Biopharmaceutical Research with AI at The HESI Annual Meeting 2020.

TUESDAY 9 JUNE | VIRTUAL EVENT

Abstract

The Health and Environmental Sciences Institute (HESI)’s mission is to develop science for a safer, more sustainable world. For HESI’s Annual Meeting 2020, our Executive board director, Jackie Hunter, will take to the virtual stage to demonstrate how AI can be used right at the beginning of the R&D process to improve target identification and validation as well as being used to identify key pathways in disease. Benevolent’s technology platform can be used to better predict the properties of molecules including their safety leading to fewer compounds needing to be physically made. There are still considerable challenges in applying the technology – primarily around access to data, especially negative data and these will be discussed.

 

Prof. Jackie Hunter, BenevolentAI

Professor Jackie Hunter held senior positions at global pharmaceutical organisations including GSK, Proximagen and OI Pharma Partners before joining BenevolentAI as an Executive Board Director in 2016. She brings vast academic and business experience in the biomedical and pharmaceutical sectors. For her services to the pharmaceutical industry, she was awarded a CBE in 2010, Birthday Honours and the 2010 Women of Achievement in Science, Engineering and Technology Award for Discovery, Innovation and Entrepreneurship. She gives the company the insight it needs to operate its unique business model – one which sees it not only researching, but also developing the blueprint for new drugs.

REGISTER >

More Posts

You Might Also Like

News
Rob Quinn to join BenevolentAI as Chief Financial Officer
Rob Quinn to join BenevolentAI as Chief Financial Officer to guide the company's growth and financial direction.
Oct 21, 2020
Blog
Data Diversity: Ten practical approaches to acquiring the right datasets Part 1
In this two-part blog, we propose ten practical approaches to improving data acquisition to encourage more inclusive research and improve the diversity of data used in drug discovery.
Oct 20, 2020
Blog
Data Diversity: Ten practical approaches to acquire the right datasets Part 2
In this two-part blog, we propose ten practical approaches to improving data acquisition to encourage more inclusive research and improve the diversity of data used in drug discovery.
Oct 20, 2020
News
NIAID releases additional data validating BenevolentAI’s hypothesis for baricitinib as a treatment for COVID-19 patients in large-scale randomised control trial
Additional data from the ACTT-2 randomised control trial shows reduced time to recovery and improved clinical outcomes for patients with COVID-19.
Oct 9, 2020
News
BenevolentAI welcomes Professor Russ Altman as scientific advisor
As a scientific advisor at BenevolentAI, Professor Russ Altman will help our scientists to further push the boundaries of machine learning applied drug discovery.
Oct 1, 2020
Blog
The Diversity Analysis Tool: Towards better Diversity in Data for Precision Medicine
As part of the data diversity initiative, our team released a simple open-source programme to evaluate the diversity of datasets and inspire others to search for solutions to drive innovation that benefits everyone.
Sep 22, 2020